Skip to main content
. Author manuscript; available in PMC: 2006 Jun 12.
Published in final edited form as: J Clin Oncol. 2005 Apr 1;23(10):2346–2357. doi: 10.1200/JCO.2005.00.240

Fig 6.

Fig 6

Transferred cells persisted for extended time in responding patients. Each tumor-infiltrating lymphocyte administered on day 0 contained a tumor reactive clone with the indicated T-cell receptor beta chain variable region (Vβ) expression or HLA-A2/MART-1-26-35 (27L) tetrameter (A2/MART-1)-binding. The percentage of CD8+ cells recognized by the indicated reagent is indicated. Pre, pretreatment peripheral blood lymphocytes (PBL). Post, PBL on the day indicated after cell transfer.